Patent US4832940A successfully refreshed from Google Patents.
US4832940A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Method of locating or imaging activated T-lymphocytes with a targeting polypeptide
Assignee: GE Healthcare AS
•
Filing: 1986-10-21
•
Granted: 1989-05-23
•
Expires: 2006-10-21
Abstract
Abstract The present invention provides targeting polypeptides for use in targeting and identifying activated T-lymphocytes in the human or animal body, the targeting polypeptides being capable of binding specifically to the interleukin-2 receptors of activated T-lymphocytes or to molecules associated with the receptors and carrying one or more physiologically compatible imaging agents. Such targeting polypeptides can be used for, example, in the location of tumours and abscesses and other inflammatory conditions and in the monitoring of tissue transplants for possible rejection.
Inventors
- 👤 Thorfinn Ege
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-27 16:19
CPC Classifications
A; A61; A61K; A61K51/00; A61K51/02; A61K51/04; A61K51/08
Claims Analysis
Total Claims: 11
Claim 1
Independent Claim
99 words
A method for locating or imaging a region containing an in vivo accumulation of activated T-lymphocytes in a subject, which comprises administering to a subject an effective amount, for locating or imaging, of a targeting polypeptide capable of binding specifically to interleukin-2 receptors of activated T-lymphocytes and carrying one or more physiologically compatible imaging agents, to bind said targeting polypeptide in vivo to interleukin-2 receptors of activated T-lymphocytes in a region containing an accumulation of said activated T-lymphocytes to locate or image said accumulation of activated T-lymphocytes, said method excluding introduction of an antibody to clear nonlocalized targeting polypeptides.
Claim 2
Independent Claim
99 words
A method for locating or imaging a region containing an in vivo accumulation of activated T-lymphocytes in a subject, which comprises administering to a subject an effective amount, for locating or imaging, of a targeting polypeptide capable of binding specifically to interleukin-2 receptors of activated T-lymphocytes and carrying one or more physiologically compatible imaging agents, to bind said targeting polypeptide in vivo to interleukin-2 receptors of activated T-lymphocytes in a region containing an accumulation of said activated T-lymphocytes to locate or image said accumulation of activated T-lymphocytes, said method excluding introduction of an antibody to clear nonlocalized targeting polypeptides.
Claim 3
Dependent Claim
14 words
A method as claimed in claim 1 in which the targeting polypeptide comprises interleukin-2.
Claim 4
Dependent Claim
26 words
A method as claimed in claim 1 in which the targeting polypeptide comprises an antibody capable of binding specifically to the interleukin-2 receptors of activated T-lymphocytes.
Claim 5
Dependent Claim
52 words
A method as claimed in claim 1 in which the targeting polypeptide is a combination of a first polypeptide capable of binding directly to the interleukin-2 receptors of activated T-lymphocytes and a second polypeptide bound to said first polypeptide, said second polypeptide having bound thereto one or more physiologically compatible imaging agents.
Claim 6
Dependent Claim
32 words
A method as claimed in claim 1 in which the targeting polypeptide carries one or more imaging agents selected from the group consisting of radionuclides, x-ray contrast agents, and NMR imaging agents.
Claim 7
Dependent Claim
42 words
A method as claimed in claim 1 in which the targeting polypeptide carries one or more imaging agents selected from the group consisting of Tc-99m, In-111, I-123 and I-131, ionic and non-ionic iodo-benzene x-ray contrast agents and paramagnetic ion NMR contrast agents.
Claim 8
Dependent Claim
17 words
A method according to claim 1 wherein the region of activated T-lymphocytes is caused by a tumor.
Claim 9
Dependent Claim
18 words
A method as claimed in claim 1 wherein the region of activated T-lymphocytes is caused by an abscess.
Claim 10
Dependent Claim
19 words
A method as claimed in claim 1 wherein the region of activated T-lymphocytes is caused by an inflammatory condition.
Claim 11
Dependent Claim
20 words
A method as claimed in claim 1 in which the region of activted T-lymphocytes is caused by tissue transplant rejection.
References Cited (Backward Citations)
US4472371A
Cited
WO1981002522A1
Cited
US4473493A
Cited
US4454106A
Cited
US4443427A
Cited
US4550086A
Cited
EP0149709A1
Cited
US4578335A
Cited
US4634586A
Cited
US4695538A
Cited
EP0173629A1
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1992-05-22 | 1992-11-21 | 1993-05-23 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1996-05-22 | 1996-11-21 | 1997-05-23 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2000-05-22 | 2000-11-21 | 2001-05-23 | $7700.00 | Window Closed / Lapsed |